Dr Paul Adams, Professor Emeritus, Western University, London, Ontario, joined the Canadian Hemochromatosis Society on October 6, 2021, to discuss his latest research paper published in the Canadian Liver Journal. The paper explores a common question amongst hemochromatosis patients: Do hemochromatosis patients treated by phlebotomy have any risk of developing serious symptoms many years later? The study took 527 C282Y homozygotes from the clinic of Dr Adams and compared them to 12,879 volunteers of similar age that participated as control participants in the Hemochromatosis and Iron Overload (HEIRS) screening study and had no genetic mutations for hemochromatosis. Ontario has a large health care database (ICES) that can track many outcomes such as death, cancer, liver disease, joint replacement, diabetes and this study followed the 2 groups for 17.7 years. The data is expressed as the hazard ratio of hemochromatosis patients compared to this normal control group. The data is similar to another paper published in England in November 2020 (UK Biobank) which studied untreated patients discovered through genetic screening. The paper for discussion is open access and can be downloaded at https://canlivj.utpjournals.press/doi....

We extend our gratitude to Dr. Paul Adams and Canadian Hemochromatosis Society members and supporters for making this session possible. Join our membership at toomuchiron.ca.